M&A / Property
AI/ML Innovations Inc. Announces Grant of U.S. Patent Protecting Core ECG Signal-Processing Architecture

AIML · Price
Executive Summary
- The United States Patent and Trademark Office issued a Notice of Allowance for U.S. Patent No. 12,465,266 covering AIML’s core machine‑learning architecture for ECG signal denoising and wave‑property identification.
- The allowed claims protect the proprietary approach used in the company’s MaxYield™ and CardioYield™ products, reinforcing its competitive advantage as it moves toward commercialization and regulatory approvals.
- Company leadership highlighted the allowance as a significant milestone that strengthens AIML’s IP portfolio and supports ongoing product deployment globally.
Key Details
- Patent Information: U.S. Patent No. 12,465,266 (Notice of Allowance) for the core ML architecture behind Neural Cloud’s ECG wave‑property identification engine.
- Scope of Protection: Broad claims covering denoising of ECG signals, beat‑level morphology identification, and association of patterns with clinically meaningful cardiac rhythm conditions.
- Strategic Impact: Enhances AIML’s intellectual property position, supporting commercialization, regulatory pathways, and clinical validation across cardiology, remote monitoring, telehealth, and research applications.
- Portfolio Context: First allowance among several pending patent applications in AIML’s IP portfolio; additional filings are underway.
- Product Linkage: Underpins downstream products MaxYield™ and CardioYield™, enabling high‑fidelity, clinically interpretable cardiac insights.
- Leadership Quotes:
- Esmat Naikyar, President of Neural Cloud – “This patent represents an exciting milestone for our platform…”.
- Paul Duffy, Executive Chairman & CEO – “The allowance validates both our technical innovation and our long‑term vision…”.
Notable Quotes
- “The core signal‑processing and wave‑morphology identification engine is what enables our downstream products—including MaxYield™ and CardioYield™—to deliver high‑fidelity, clinically interpretable cardiac insights.” – Esmat Naikyar
- “It provides strong protection around the architecture we have developed, positioning AIML with a meaningful competitive advantage as we advance commercialization.” – Paul Duffy
More from AI-ML Innovations Inc.
Jun 23, 2026 · 07:00